{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:40:14Z","timestamp":1770331214605,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"am","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neurol.2022.12.004","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T18:01:53Z","timestamp":1672855313000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The new horizons for treatment of Late-Onset Pompe Disease (LOPD)"],"prefix":"10.1016","volume":"179","author":[{"given":"C.","family":"Gu\u00e9my","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2022.12.004_bib0235","first-page":"928","article-title":"From basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"10.1016\/j.neurol.2022.12.004_bib0240","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neurol.2013.07.002","article-title":"The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease","volume":"169","author":"Lafor\u00eat","year":"2013","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2022.12.004_bib0245","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10545-018-0243-7","article-title":"Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study","volume":"41","author":"Semplicini","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.neurol.2022.12.004_bib0250","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.12.004_bib0255","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.12.004_bib0260","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.12.004_bib0265","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jimd.12272","article-title":"Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry","volume":"43","author":"Semplicini","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.neurol.2022.12.004_bib0270","doi-asserted-by":"crossref","first-page":"50336","DOI":"10.1074\/jbc.M409676200","article-title":"Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice","volume":"279","author":"Zhu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurol.2022.12.004_bib0275","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/auto.6.8.13378","article-title":"Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder\u00a0\u2013\u00a0murine Pompe disease","volume":"6","author":"Raben","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.neurol.2022.12.004_bib0280","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BJ20050364","article-title":"Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"389","author":"Zhu","year":"2005","journal-title":"Biochem J"},{"key":"10.1016\/j.neurol.2022.12.004_bib0285","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0290","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.12.004_bib0295","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0300","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A chaperone enhances blood \u03b1-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0305","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.12.004_bib0310","doi-asserted-by":"crossref","first-page":"14774","DOI":"10.1002\/anie.201607824","article-title":"Design of potent mannose 6-phosphate analogues for the functionalization of lysosomal enzymes to improve the treatment of pompe disease","volume":"55","author":"El Cheikh","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.neurol.2022.12.004_bib0315","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2017.10.043","article-title":"Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid \u03b1-glucosidase","volume":"269","author":"Basile","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.neurol.2022.12.004_bib0320","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid \u03b1-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurol.2022.12.004_bib0325","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/jpet.116.235952","article-title":"Reveglucosidase alfa (BMN 701), an IGF2-tagged rhAcid \u03b1-glucosidase, improves respiratory functional parameters in a murine model of Pompe disease","volume":"360","author":"Peng","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0330","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-017-0693-2","article-title":"A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease","volume":"12","author":"Byrne","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurol.2022.12.004_bib0335","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease","volume":"95","author":"Yi","year":"2017","journal-title":"J Mol Med Berl Ger"},{"key":"10.1016\/j.neurol.2022.12.004_bib0340","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.neurol.2022.12.004_bib0345","first-page":"31","article-title":"Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease","volume":"11","author":"Chien","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.neurol.2022.12.004_bib0350","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological enhancement of \u03b1-glucosidase by the allosteric chaperone N-acetylcysteine","volume":"20","author":"Porto","year":"2012","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0355","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2008.010","article-title":"Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice","volume":"19","author":"Ziegler","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0360","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","article-title":"Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II","volume":"14","author":"Sun","year":"2006","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0365","first-page":"9","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","author":"Puzzo","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurol.2022.12.004_bib0370","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/mt.2009.305","article-title":"Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease","volume":"18","author":"Mah","year":"2010","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0375","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0380","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.neurol.2022.12.004_bib0385","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/mt.2011.214","article-title":"Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice","volume":"20","author":"Qiu","year":"2012","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0390","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2013.96","article-title":"Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease","volume":"21","author":"Falk","year":"2013","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0395","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice","volume":"22","author":"Elmallah","year":"2014","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0400","first-page":"6","article-title":"The use of tricyclo-DNA oligomers for the treatment of genetic disorders","author":"Aupy","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.neurol.2022.12.004_bib0405","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2022.12.004_bib0410","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne's muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.12.004_bib0415","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2022.12.004_bib0420","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","article-title":"Efficacy and safety profile of tricyclo-DNA antisense oligonucleotides in duchenne muscular dystrophy mouse model","volume":"8","author":"Relizani","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.neurol.2022.12.004_bib0425","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/humu.21160","article-title":"Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping","volume":"31","author":"Wein","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.neurol.2022.12.004_bib0430","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.12.004_bib0435","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.12.004_bib0440","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ymthe.2017.05.019","article-title":"Glycogen reduction in myotubes of late-onset pompe disease patients using antisense technology","volume":"25","author":"Goina","year":"2017","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.neurol.2022.12.004_bib0445","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omtn.2017.03.001","article-title":"Antisense oligonucleotides promote exon inclusion and correct the common c.-32-13T>G GAA splicing variant in pompe disease","volume":"7","author":"van der Wal","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.neurol.2022.12.004_bib0450","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.omtn.2017.03.002","article-title":"GAA deficiency in Pompe disease is alleviated by exon inclusion in iPSC-derived skeletal muscle cells","volume":"7","author":"van der Wal","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.neurol.2022.12.004_bib0455","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1038\/mtna.2016.75","article-title":"From cryptic toward canonical pre-mRNA splicing in Pompe disease: a pipeline for the development of antisense oligonucleotides","volume":"5","author":"Bergsma","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.neurol.2022.12.004_bib0460","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1038\/mtna.2014.57","article-title":"Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease","volume":"3","author":"Clayton","year":"2014","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722008475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722008475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:45:34Z","timestamp":1758519934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722008475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":46,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0035378722008475"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.12.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The new horizons for treatment of Late-Onset Pompe Disease (LOPD)","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}